Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS

Go back to Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
(NASDAQ: IONS) Delayed: 36.54 -0.79 (2.12%)
Previous Close $37.33    52 Week High $62.68 
Open $37.83    52 Week Low $19.59 
Day High $39.34    P/E N/A 
Day Low $36.37    EPS $0.00 
Volume 2,696,020